---
title: "GH Research publishes corporate presentation on ultra-rapid, durable remission data for TRD treatment GH001"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295098135.md"
description: "GH Research published a corporate presentation highlighting Phase 2b data for GH001, an inhaled mebufotenin candidate for treatment-resistant depression. The drug showed significant efficacy with a MADRS change difference of -15.5 versus placebo on Day 8 and a 57.5% remission rate. The presentation emphasized a short psychoactive phase suitable for outpatient use. As of June 30, 2026, the company held $362.7 million in cash and securities, targeting Phase 3 initiation in 2026."
datetime: "2026-08-06T11:19:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295098135.md)
  - [en](https://longbridge.com/en/news/295098135.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295098135.md)
generator: "portal-rs"
---

# GH Research publishes corporate presentation on ultra-rapid, durable remission data for TRD treatment GH001

-   GH Research highlighted Phase 2b data for GH001, an inhaled mebufotenin candidate for treatment-resistant depression. \* Primary endpoint showed a least-squares mean MADRS change difference of -15.5 versus placebo on Day 8 (P<0.0001); Cohen’s d -2. \* Remission (MADRS ≤10) reached 57.5% on Day 8; open-label extension completers showed 73% remission at 6 months. \* Presentation emphasized an ~11-minute median psychoactive phase, positioning GH001 for a Spravato-compatible outpatient clinic workflow. \* Cash, cash equivalents, and marketable securities totaled $362.7 million as of June 30, 2026; Phase 3 initiation targeted in 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GH Research plc published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [GHRS.US](https://longbridge.com/en/quote/GHRS.US.md)

## Related News & Research

- [Avalyn Announces Multiple Presentations at the European Respiratory Society International Congress 2026 | AVLN Stock News](https://longbridge.com/en/news/296823873.md)
- [B2 Impact publishes credit investor presentation for fixed income meetings](https://longbridge.com/en/news/297008022.md)
- [Rein Therapeutics releases corporate presentation on LTI-03 idiopathic pulmonary fibrosis program](https://longbridge.com/en/news/296389731.md)
- [Exmar announces availability of 2026 half-year results release](https://longbridge.com/en/news/296992548.md)
- [Biovica signs master services agreement with US biotech subsidiary for cancer drug development testing services](https://longbridge.com/en/news/297162314.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**